Literature DB >> 17344255

Respiratory function during parenteral opioid titration for cancer pain.

Bassam Estfan1, Fade Mahmoud, Philip Shaheen, Mellar P Davis, Wael Lasheen, Nilo Rivera, Susan B Legrand, Ruth L Lagman, Declan Walsh, Lisa Rybicki.   

Abstract

BACKGROUND: Respiratory depression is the most feared opioid-related side-effect yet research on the topic is sparse. We evaluated changes in respiratory parameters during parenteral opioid titration for cancer pain to determine if opioid titration was associated with evidence of hypoventilation. The primary outcome measure was to measure changes in end-tidal CO(2) (ET-CO(2)) during opioid titration to pain control.
METHODS: Subjects with severe cancer pain admitted for parenteral opioid titration for poorly controlled pain were eligible. Those who were oxygen dependent were excluded. ET-CO(2), O(2) saturation, respiratory rate (RR), and vital signs were monitored daily until pain control was achieved.
RESULTS: 30 patients completed the study of which 29 are reported. The mean ET-CO(2) at initial evaluation was 33.39 -/+ 5.0 and 34.79 -/+ 5.7 mmHg at pain control (P =0.14, 95% CI -0.5 to 3.3). None had an ET-CO(2) > or =50 mmHg. All maintained O(2) saturation > or = 92%. RR dropped transiently below 10/minute in two subjects.
CONCLUSIONS: Parenteral opioid titration for relief of cancer pain was not associated with respiratory depression as demonstrated by significant changes in ET-CO(2) or oxygen saturation in non-oxygen dependent cancer patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344255     DOI: 10.1177/0269216307077328

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  15 in total

1.  Ethical and legal issues in end-of-life care.

Authors:  Andrew Thorns
Journal:  Clin Med (Lond)       Date:  2010-06       Impact factor: 2.659

2.  Killing the symptom without killing the patient.

Authors:  Romayne Gallagher
Journal:  Can Fam Physician       Date:  2010-06       Impact factor: 3.275

3.  [The right to pain treatment--obligatory continuing education].

Authors:  M Zenz
Journal:  Schmerz       Date:  2011-02       Impact factor: 1.107

4.  [Combined use of bucolome and pyrazolone derivatives (II). Complex formation due to interaction between bucolome and pyrazolones].

Authors:  M Nozaki
Journal:  Nihon Yakurigaku Zasshi       Date:  1975-09

5.  Use of opioid analgesics among older persons with colorectal cancer in two health districts with palliative care programs.

Authors:  Judith Fisher; Robin Urquhart; Grace Johnston
Journal:  J Pain Symptom Manage       Date:  2012-09-24       Impact factor: 3.612

Review 6.  [Limits of pain treatment: medical and judicial aspects].

Authors:  M Zenz; R Rissing-van Saan
Journal:  Schmerz       Date:  2011-08       Impact factor: 1.107

7.  A comparison of the effects of hydromorphone HCl and a novel extended release hydromorphone on arterial blood gas values in conscious healthy dogs.

Authors:  L A Wunsch; B K Schmidt; L A Krugner-Higby; L J Smith
Journal:  Res Vet Sci       Date:  2009-08-18       Impact factor: 2.534

8.  The use of opioids at the end of life: knowledge level of pharmacists and cooperation with physicians.

Authors:  Sander D Borgsteede; Christiaan A Rhodius; Peter A G M De Smet; H Roeline W Pasman; Bregje D Onwuteaka-Philipsen; Mette L Rurup
Journal:  Eur J Clin Pharmacol       Date:  2010-09-19       Impact factor: 2.953

9.  The use of opioids at the end of life: the knowledge level of Dutch physicians as a potential barrier to effective pain management.

Authors:  Mette L Rurup; Christiaan A Rhodius; Sander D Borgsteede; Manon Sa Boddaert; Astrid Gm Keijser; H Roeline W Pasman; Bregje D Onwuteaka-Philipsen
Journal:  BMC Palliat Care       Date:  2010-11-12       Impact factor: 3.234

Review 10.  End of life care in chronic obstructive pulmonary disease: in search of a good death.

Authors:  Anna Spathis; Sara Booth
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.